
    
      ROSY-O is an open label, non-randomised, multicentre,international trial for patients who
      have completed a parent study using olaparib and who are deriving clinical benefit from
      continued treatment as judged by the Investigator. Patients will be rolled-over from the
      parent study and will continue the study indefinitely, until they meet one of the treatment
      discontinuation criteria
    
  